BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32171711)

  • 21. Building an adverse outcome pathway network for estrogen-, androgen- and steroidogenesis-mediated reproductive toxicity.
    Zilliacus J; Draskau MK; Johansson HKL; Svingen T; Beronius A
    Front Toxicol; 2024; 6():1357717. PubMed ID: 38601197
    [No Abstract]   [Full Text] [Related]  

  • 22. Current limitations and recommendations to improve testing for the environmental assessment of endocrine active substances.
    Coady KK; Biever RC; Denslow ND; Gross M; Guiney PD; Holbech H; Karouna-Renier NK; Katsiadaki I; Krueger H; Levine SL; Maack G; Williams M; Wolf JC; Ankley GT
    Integr Environ Assess Manag; 2017 Mar; 13(2):302-316. PubMed ID: 27791330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ECETOC Florence workshop on risk assessment of endocrine substances, including the potency concept.
    Fegert I
    Toxicol Lett; 2013 Dec; 223(3):310-4. PubMed ID: 23558296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypothesis-driven weight of evidence evaluation indicates styrene lacks endocrine disruption potential.
    Borgert CJ
    Crit Rev Toxicol; 2023 Feb; 53(2):53-68. PubMed ID: 37216681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive review of regulatory test methods for endocrine adverse health effects.
    Manibusan MK; Touart LW
    Crit Rev Toxicol; 2017 Jul; 47(6):433-481. PubMed ID: 28617201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In utero exposure to bisphenol-A disrupts key elements of retinoid system in male mice offspring.
    Esteban J; Serrano-Maciá M; Sánchez-Pérez I; Alonso-Magdalena P; Pellín MC; García-Arévalo M; Nadal Á; Barril J
    Food Chem Toxicol; 2019 Apr; 126():142-151. PubMed ID: 30790712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of in vivo assays for endocrine disruption.
    Clode SA
    Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):35-43. PubMed ID: 16522518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of endocrine disrupting chemicals on neurodevelopment: the need for better testing strategies for endocrine disruption-induced developmental neurotoxicity.
    Cediel-Ulloa A; Lupu DL; Johansson Y; Hinojosa M; Özel F; Rüegg J
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):131-141. PubMed ID: 35255767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limits of the regulatory evaluation of resorcinol as a thyroid disruptor: When limited experimental data challenge established effects in humans.
    Pasquier E; Viguié C; Fini JB; Mhaouty-Kodja S; Michel-Caillet C
    Environ Res; 2023 Apr; 222():115330. PubMed ID: 36693459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells.
    Lee HY; Dawson MI; Walsh GL; Nesbitt JC; Eckert RL; Fuchs E; Hong WK; Lotan R; Kurie JM
    Cell Growth Differ; 1996 Aug; 7(8):997-1004. PubMed ID: 8853895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Minderoo-Monaco Commission on Plastics and Human Health.
    Landrigan PJ; Raps H; Cropper M; Bald C; Brunner M; Canonizado EM; Charles D; Chiles TC; Donohue MJ; Enck J; Fenichel P; Fleming LE; Ferrier-Pages C; Fordham R; Gozt A; Griffin C; Hahn ME; Haryanto B; Hixson R; Ianelli H; James BD; Kumar P; Laborde A; Law KL; Martin K; Mu J; Mulders Y; Mustapha A; Niu J; Pahl S; Park Y; Pedrotti ML; Pitt JA; Ruchirawat M; Seewoo BJ; Spring M; Stegeman JJ; Suk W; Symeonides C; Takada H; Thompson RC; Vicini A; Wang Z; Whitman E; Wirth D; Wolff M; Yousuf AK; Dunlop S
    Ann Glob Health; 2023; 89(1):23. PubMed ID: 36969097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders-An Introduction to the OBERON Project.
    Audouze K; Sarigiannis D; Alonso-Magdalena P; Brochot C; Casas M; Vrijheid M; Babin PJ; Karakitsios S; Coumoul X; Barouki R
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight-of-the-evidence evaluation of 2,4-D potential for interactions with the estrogen, androgen and thyroid pathways and steroidogenesis.
    Neal BH; Bus J; Marty MS; Coady K; Williams A; Staveley J; Lamb JC
    Crit Rev Toxicol; 2017 May; 47(5):345-401. PubMed ID: 28303741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential regulation of human ectocervical epithelial cell line proliferation and differentiation by retinoid X receptor- and retinoic acid receptor-specific retinoids.
    Agarwal C; Chandraratna RA; Teng M; Nagpal S; Rorke EA; Eckert RL
    Cell Growth Differ; 1996 Apr; 7(4):521-30. PubMed ID: 9052993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and metabolic retinoid pathways in the human ocular surface.
    Nezzar H; Chiambaretta F; Marceau G; Blanchon L; Faye B; Dechelotte P; Rigal D; Sapin V
    Mol Vis; 2007 Sep; 13():1641-50. PubMed ID: 17893666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of non-validated endocrine disrupting chemical characterization methods by screening of the literature using artificial intelligence and by database exploration.
    Zgheib E; Kim MJ; Jornod F; Bernal K; Tomkiewicz C; Bortoli S; Coumoul X; Barouki R; De Jesus K; Grignard E; Hubert P; Katsanou ES; Busquet F; Audouze K
    Environ Int; 2021 Sep; 154():106574. PubMed ID: 33895441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary specific retinoid-X receptor ligand interactions with thyroid hormone receptor signaling revealed by high throughput reporter and endogenous gene responses.
    Mengeling BJ; Furlow JD
    Toxicol In Vitro; 2015 Oct; 29(7):1609-18. PubMed ID: 26096596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The European strategy on endocrine disrupters: progress to date and EU/US cooperation.
    Bontoux L
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():9-11. PubMed ID: 11820642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of retinoids, rexinoids and thyroid hormone in the expression of cytochrome p450 enzymes.
    Brtko J; Dvorak Z
    Curr Drug Metab; 2011 Feb; 12(2):71-88. PubMed ID: 21401514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinoids and rexinoids in cancer prevention: from laboratory to clinic.
    Uray IP; Dmitrovsky E; Brown PH
    Semin Oncol; 2016 Feb; 43(1):49-64. PubMed ID: 26970124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.